Yes, targeting the TME is a promising strategy in cancer therapy. Approaches include: 1. Anti-angiogenic Therapy: Drugs like bevacizumab inhibit blood vessel formation, starving the tumor of nutrients. 2. Immune Modulation:Checkpoint inhibitors such as pembrolizumab can enhance the anti-tumor activity of immune cells. 3. Matrix Modulation: Enzymes that degrade the ECM can improve the delivery and efficacy of chemotherapeutic agents.
